HDAC9 and atherosclerosis: A study in an atherosclerosis animal model demonstrated that Endo-Hdac9KO or class IIa HDAC inhibitor (MC1568) treatment significantly attenuated the progression of atherosclerosis by reducing plaque area and enhancing plaque stabilization, even though further investigation is acquired (Lecce et al., 2021).